米国のアンチセンスおよびRNAi治療薬の市場規模は、2023年に27億6,000万ドルと推定され、2024年から2030年にかけて19.10%のCAGRで成長すると予想されます。さまざまな疾患におけるアンチセンス技術の学際的な応用、がんの有病率の増加、政府の有利なイニシアチブと資金提供が市場の成長を後押ししています。さらに、RNAi治療薬を開発するための主要企業によるパートナーシップの増加が、成長を加速させると予想されます。2023年、米国は世界のアンチセンスおよびRNAi治療薬市場で63.0%のシェアを占めました。政府による研究開発活動への取り組みと財政支援がバイオ医薬品企業の成長を支えています。これらの政府の戦略は、認知度を高め、市場でのアンチセンスおよびRNAi治療薬の製造の引き金になることを目的としています。さらに、外部助成金の供与により、市場での新規治療薬の発売と、国内の疾病負担を軽減するための医薬品の開発が促進されます。これらの動向は、市場の成長機会をさらに加速させます。
目次
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Application
1.2.3. Route of administration
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in Italy
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Technology
2.2.2. Application
2.2.3. Route of administration
2.3. Competitive Insights
Chapter 3. U.S. Antisense and RNAi Therapeutics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. U.S. Antisense and RNAi Therapeutics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.2. PESTEL Analysis
Chapter 4. U.S. Antisense and RNAi Therapeutics Market Technology Estimates & Trend Analysis
4.1. U.S. Antisense and RNAi Therapeutics Market Technology Dashboard
4.2. U.S. Antisense and RNAi Therapeutics Market Technology Movement Analysis
4.3. U.S. Antisense and RNAi Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030
4.4. RNA Interference
4.4.1. RNA Interference Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Antisense RNA
4.5.1. Antisense RNA Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Antisense and RNAi Therapeutics Market: Application Estimates & Trend Analysis
5.1. U.S. Antisense and RNAi Therapeutics Market Application Dashboard
5.2. U.S. Antisense and RNAi Therapeutics Market Application Movement Analysis
5.3. U.S. Antisense and RNAi Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.4. Ocular
5.4.1. Ocular market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Cardio metabolic & Renal Disorders
5.5.1. Cardio metabolic & renal disorders market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Neurodegenerative Disorders
5.6.1. Neurodegenerative Disorders Market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Genetic Disorders
5.7.1. Genetic Disorders Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Antisense and RNAi Therapeutics Market: Route of Administration Estimates & Trend Analysis
6.1. U.S. Antisense and RNAi Therapeutics Market Application Dashboard
6.2. U.S. Antisense and RNAi Therapeutics Market Application Movement Analysis
6.3. U.S. Antisense and RNAi Therapeutics Market Size & Forecasts and Trend Analyses, 2018 to 2030
6.4. Intravenous Injections
6.4.1. Intravenous Injections Market Estimates and Forecasts 2018 to 2030 (USD million)
6.5. Intrathecal Injections
6.5.1. Intrathecal Injections Market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Subcutaneous Injections
6.6.1. Subcutaneous Injections Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.2.1. Key company market share analysis, 2023
7.3. Vendor Landscape
7.3.1. Sarepta Therapeutics, Inc
7.3.1.1. Company overview
7.3.1.2. Financial performance
7.3.1.3. Product benchmarking
7.3.1.4. Strategic initiatives
7.3.2. Ionis Pharmaceuticals, Inc
7.3.2.1. Company overview
7.3.2.2. Financial performance
7.3.2.3. Product benchmarking
7.3.2.4. Strategic initiatives
7.3.3. Benitec Biopharma, Inc.
7.3.3.1. Company overview
7.3.3.2. Financial performance
7.3.3.3. Product benchmarking
7.3.3.4. Strategic initiatives
7.3.4. Arbutus Biopharma
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Alnylam Pharmaceuticals, Inc.
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Microsynth AG
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Aragen Bioscience
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Moderna
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Nutcracker Therapeutics
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Deep Genomics
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
List of Tables
Table 1 List of abbreviations
Table 2 U.S. Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Billion)
Table 3 U.S. Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Billion)
Table 4 U.S. Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Billion)
List of Figures
Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 U.S. Antisense and RNAi Therapeutics Market Segmentation
Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 U.S. Antisense and RNAi Therapeutics Market: Technology outlook and key takeaways
Fig. 15 U.S. Antisense and RNAi Therapeutics Market: Technology Movement Analysis & Market Share 2023 & 2030
Fig. 16 RNA interference market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 17 U.S. Antisense RNA market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 U.S. Antisense and RNAi Therapeutics Market: Application outlook and key takeaways
Fig. 19 U.S. Antisense and RNAi Therapeutics market: Application movement analysis & market share 2023 & 2030
Fig. 20 Ocular market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Cardiometabolic & renal disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Neurodegenerative disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Genetic disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 U.S. Antisense and RNAi Therapeutics Market: Route of Administration outlook and key takeaways
Fig. 25 U.S. Antisense and RNAi Therapeutics market: Route of Administration movement analysis & market share 2023 & 2030
Fig. 26 Intravenous injections market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Intrathecal injections market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Subcutaneous injections market estimates and forecasts, 2018 - 2030 (USD Million)
